CN108137582A - 作为双重DYRK1/CLK1抑制剂的新的吡咯并[2,3-d]嘧啶衍生物 - Google Patents

作为双重DYRK1/CLK1抑制剂的新的吡咯并[2,3-d]嘧啶衍生物 Download PDF

Info

Publication number
CN108137582A
CN108137582A CN201680058179.3A CN201680058179A CN108137582A CN 108137582 A CN108137582 A CN 108137582A CN 201680058179 A CN201680058179 A CN 201680058179A CN 108137582 A CN108137582 A CN 108137582A
Authority
CN
China
Prior art keywords
formula
methyl
pyrrolo
compound
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201680058179.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·菲乌马纳
N·弗洛派
S·雷
D·沃姆斯利
A·科斯基
M·F·博布里奇
F·H·克鲁扎勒圭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Original Assignee
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Furnalis R&d Co ltd, Les Laboratoires Servier SAS filed Critical Furnalis R&d Co ltd
Publication of CN108137582A publication Critical patent/CN108137582A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680058179.3A 2015-09-30 2016-09-30 作为双重DYRK1/CLK1抑制剂的新的吡咯并[2,3-d]嘧啶衍生物 Withdrawn CN108137582A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR15/59259 2015-09-30
FR1559259A FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
PCT/EP2016/073403 WO2017055533A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors

Publications (1)

Publication Number Publication Date
CN108137582A true CN108137582A (zh) 2018-06-08

Family

ID=54979756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680058179.3A Withdrawn CN108137582A (zh) 2015-09-30 2016-09-30 作为双重DYRK1/CLK1抑制剂的新的吡咯并[2,3-d]嘧啶衍生物

Country Status (26)

Country Link
US (1) US20180273538A1 (cg-RX-API-DMAC10.html)
EP (1) EP3356364A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018533552A (cg-RX-API-DMAC10.html)
KR (1) KR20180054856A (cg-RX-API-DMAC10.html)
CN (1) CN108137582A (cg-RX-API-DMAC10.html)
AU (1) AU2016333508A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018005851A2 (cg-RX-API-DMAC10.html)
CA (1) CA2999937A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018000786A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018003466A2 (cg-RX-API-DMAC10.html)
CR (1) CR20180176A (cg-RX-API-DMAC10.html)
CU (1) CU20180027A7 (cg-RX-API-DMAC10.html)
DO (1) DOP2018000082A (cg-RX-API-DMAC10.html)
EA (1) EA201890820A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP18023286A (cg-RX-API-DMAC10.html)
FR (1) FR3041640B1 (cg-RX-API-DMAC10.html)
HK (1) HK1255467A1 (cg-RX-API-DMAC10.html)
IL (1) IL258231A (cg-RX-API-DMAC10.html)
MA (1) MA43021A (cg-RX-API-DMAC10.html)
MX (1) MX2018003861A (cg-RX-API-DMAC10.html)
NI (1) NI201800042A (cg-RX-API-DMAC10.html)
PE (1) PE20190337A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018500605A1 (cg-RX-API-DMAC10.html)
SV (1) SV2018005656A (cg-RX-API-DMAC10.html)
TN (1) TN2018000087A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017055533A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
CN113164476A (zh) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Dyrk1/clk的小分子抑制剂及其用途
CN115785134A (zh) * 2022-10-28 2023-03-14 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用
CN116783198A (zh) * 2020-12-02 2023-09-19 百极弘烨(广东)医药科技有限公司 螺环jak抑制剂、含其的药物组合物及其应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
WO2022245776A1 (en) * 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment
WO2023064349A1 (en) * 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors
TW202330533A (zh) * 2021-10-12 2023-08-01 美商生物銜接醫療公司 7h-吡咯并[2,3-d]嘧啶及其製備及用途
MX2024004552A (es) 2021-10-12 2024-06-04 Biosplice Therapeutics Inc Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas.
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
JP2009511527A (ja) 2005-10-13 2009-03-19 グラクソ グループ リミテッド Syk阻害物質としてのピロロピリミジン誘導体
CA2645343A1 (en) 2006-03-11 2007-09-20 Vernalis (R&D) Limited Pyrrolopyrimidine derivatives used as hsp90 inhibitors
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EA025186B1 (ru) * 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
EP3083618B1 (en) * 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164476A (zh) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Dyrk1/clk的小分子抑制剂及其用途
US12054483B2 (en) 2018-09-28 2024-08-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
CN116783198A (zh) * 2020-12-02 2023-09-19 百极弘烨(广东)医药科技有限公司 螺环jak抑制剂、含其的药物组合物及其应用
CN116783198B (zh) * 2020-12-02 2025-10-21 广东弘烨医药科技有限公司 螺环jak抑制剂、含其的药物组合物及其应用
CN115785134A (zh) * 2022-10-28 2023-03-14 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用
WO2024087419A1 (zh) * 2022-10-28 2024-05-02 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Also Published As

Publication number Publication date
FR3041640A1 (cg-RX-API-DMAC10.html) 2017-03-31
CR20180176A (es) 2018-05-31
AU2016333508A1 (en) 2018-04-12
MA43021A (fr) 2018-08-08
WO2017055533A1 (en) 2017-04-06
EP3356364A1 (en) 2018-08-08
DOP2018000082A (es) 2018-10-15
CO2018003466A2 (es) 2018-07-10
NI201800042A (es) 2018-06-21
PH12018500605A1 (en) 2018-09-24
JP2018533552A (ja) 2018-11-15
ECSP18023286A (es) 2018-04-30
PE20190337A1 (es) 2019-03-07
HK1255467A1 (zh) 2019-08-16
US20180273538A1 (en) 2018-09-27
MX2018003861A (es) 2018-08-16
KR20180054856A (ko) 2018-05-24
TN2018000087A1 (en) 2019-07-08
BR112018005851A2 (pt) 2018-10-09
IL258231A (en) 2018-05-31
FR3041640B1 (fr) 2019-05-17
EA201890820A1 (ru) 2018-10-31
CU20180027A7 (es) 2018-07-05
SV2018005656A (es) 2018-08-10
CL2018000786A1 (es) 2018-09-28
CA2999937A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
HK1255467A1 (zh) 作为双重dyrk1/clk1抑制剂的新的吡咯并[2,3-d]嘧啶衍生物
CN115996929B (zh) 腺苷A2a受体的拮抗剂
CA2990089C (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
CN109311888B (zh) 哌啶基衍生物,其制备方法和含有它们的药物组合物
CN103974948B (zh) 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑
AU2009314544C1 (en) PI3K/mTOR kinase inhibitors
US20120309739A1 (en) Akt / pkb inhibitors
CN109963852B (zh) 氧代异喹啉衍生物
CN106928219B (zh) 含氮稠杂环化合物、制备方法、中间体、组合物和应用
US10414769B2 (en) 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
AU2010267815B2 (en) Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof
JP2008505084A (ja) フラノピリミジン
HK1210608A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
AU2018337138B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
KR20180082432A (ko) 비시클릭 화합물 및 suv39h2 를 저해하기 위한 이의 용도
KR20160127826A (ko) 비장 티로신 키나제 억제제로서 치환된 옥사졸 유도체
WO2023107603A1 (en) Pyrimidines and methods of their use
OA18644A (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual DYRK1/CLK1 inhibitors.
CN121816347A (zh) 药物化合物
EA049140B1 (ru) Замещенные конденсированные гетероароматические бициклические соединения в качестве ингибиторов киназ и их применение
HK40120946A (en) Antagonist of adenosine receptors
WO2024061118A1 (zh) 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
CN119137118A (zh) 腺苷受体的拮抗剂
HK40009542A (en) Novel oxoisoquinoline derivative
OA18890A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20180608

WW01 Invention patent application withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255467

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1255467

Country of ref document: HK